Triglyceride deposit cardiomyovasculopathy: A rare cardiovascular disorder

Ming Li, Ken Ichi Hirano, Yoshihiko Ikeda, Masahiro Higashi, Chikako Hashimoto, Bo Zhang, Junji Kozawa, Koichiro Sugimura, Hideyuki Miyauchi, Akira Suzuki, Yasuhiro Hara, Atsuko Takagi, Yasuyuki Ikeda, Kazuhiro Kobayashi, Yoshiaki Futsukaichi, Nobuhiro Zaima, Satoshi Yamaguchi, Rojeet Shrestha, Hiroshi Nakamura, Katsuhiro KawaguchiEiryu Sai, Shu Ping Hui, Yusuke Nakano, Akinori Sawamura, Tohru Inaba, Yasuhiko Sakata, Yoko Yasui, Yasuyuki Nagasawa, Shintaro Kinugawa, Kazunori Shimada, Sohsuke Yamada, Hiroyuki Hao, Daisaku Nakatani, Tomomi Ide, Tetsuya Amano, Hiroaki Naito, Hironori Nagasaka, Kunihisa Kobayashi

Research output: Contribution to journalArticle

Abstract

Triglyceride deposit cardiomyovasculopathy (TGCV) is a phenotype primarily reported in patients carrying genetic mutations in PNPLA2 encoding adipose triglyceride lipase (ATGL) which releases long chain fatty acid (LCFA) as a major energy source by the intracellular TG hydrolysis. These patients suffered from intractable heart failure requiring cardiac transplantation. Moreover, we identified TGCV patients without PNPLA2 mutations based on pathological and clinical studies. We provided the diagnostic criteria, in which TGCV with and without PNPLA2 mutations were designated as primary TGCV (P-TGCV) and idiopathic TGCV (I-TGCV), respectively. We hereby report clinical profiles of TGCV patients. Between 2014 and 2018, 7 P-TGCV and 18 I-TGCV Japanese patients have been registered in the International Registry. Patients with I-TGCV, of which etiologies and causes are not known yet, suffered from adult-onset severe heart disease, including heart failure and coronary artery disease, associated with a marked reduction in ATGL activity and myocardial washout rate of LCFA tracer, as similar to those with P-TGCV. The present first registry-based study showed that TGCV is an intractable, at least at the moment, and heterogeneous cardiovascular disorder.

Original languageEnglish
Article number134
JournalOrphanet Journal of Rare Diseases
Volume14
Issue number1
DOIs
Publication statusPublished - Jun 11 2019

Fingerprint

Triglycerides
Lipase
Mutation
Registries
Fatty Acids
Heart Failure
Heart Transplantation
Coronary Artery Disease
Heart Diseases
Hydrolysis
Phenotype

All Science Journal Classification (ASJC) codes

  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

Li, M., Hirano, K. I., Ikeda, Y., Higashi, M., Hashimoto, C., Zhang, B., ... Kobayashi, K. (2019). Triglyceride deposit cardiomyovasculopathy: A rare cardiovascular disorder. Orphanet Journal of Rare Diseases, 14(1), [134]. https://doi.org/10.1186/s13023-019-1087-4

Triglyceride deposit cardiomyovasculopathy : A rare cardiovascular disorder. / Li, Ming; Hirano, Ken Ichi; Ikeda, Yoshihiko; Higashi, Masahiro; Hashimoto, Chikako; Zhang, Bo; Kozawa, Junji; Sugimura, Koichiro; Miyauchi, Hideyuki; Suzuki, Akira; Hara, Yasuhiro; Takagi, Atsuko; Ikeda, Yasuyuki; Kobayashi, Kazuhiro; Futsukaichi, Yoshiaki; Zaima, Nobuhiro; Yamaguchi, Satoshi; Shrestha, Rojeet; Nakamura, Hiroshi; Kawaguchi, Katsuhiro; Sai, Eiryu; Hui, Shu Ping; Nakano, Yusuke; Sawamura, Akinori; Inaba, Tohru; Sakata, Yasuhiko; Yasui, Yoko; Nagasawa, Yasuyuki; Kinugawa, Shintaro; Shimada, Kazunori; Yamada, Sohsuke; Hao, Hiroyuki; Nakatani, Daisaku; Ide, Tomomi; Amano, Tetsuya; Naito, Hiroaki; Nagasaka, Hironori; Kobayashi, Kunihisa.

In: Orphanet Journal of Rare Diseases, Vol. 14, No. 1, 134, 11.06.2019.

Research output: Contribution to journalArticle

Li, M, Hirano, KI, Ikeda, Y, Higashi, M, Hashimoto, C, Zhang, B, Kozawa, J, Sugimura, K, Miyauchi, H, Suzuki, A, Hara, Y, Takagi, A, Ikeda, Y, Kobayashi, K, Futsukaichi, Y, Zaima, N, Yamaguchi, S, Shrestha, R, Nakamura, H, Kawaguchi, K, Sai, E, Hui, SP, Nakano, Y, Sawamura, A, Inaba, T, Sakata, Y, Yasui, Y, Nagasawa, Y, Kinugawa, S, Shimada, K, Yamada, S, Hao, H, Nakatani, D, Ide, T, Amano, T, Naito, H, Nagasaka, H & Kobayashi, K 2019, 'Triglyceride deposit cardiomyovasculopathy: A rare cardiovascular disorder', Orphanet Journal of Rare Diseases, vol. 14, no. 1, 134. https://doi.org/10.1186/s13023-019-1087-4
Li, Ming ; Hirano, Ken Ichi ; Ikeda, Yoshihiko ; Higashi, Masahiro ; Hashimoto, Chikako ; Zhang, Bo ; Kozawa, Junji ; Sugimura, Koichiro ; Miyauchi, Hideyuki ; Suzuki, Akira ; Hara, Yasuhiro ; Takagi, Atsuko ; Ikeda, Yasuyuki ; Kobayashi, Kazuhiro ; Futsukaichi, Yoshiaki ; Zaima, Nobuhiro ; Yamaguchi, Satoshi ; Shrestha, Rojeet ; Nakamura, Hiroshi ; Kawaguchi, Katsuhiro ; Sai, Eiryu ; Hui, Shu Ping ; Nakano, Yusuke ; Sawamura, Akinori ; Inaba, Tohru ; Sakata, Yasuhiko ; Yasui, Yoko ; Nagasawa, Yasuyuki ; Kinugawa, Shintaro ; Shimada, Kazunori ; Yamada, Sohsuke ; Hao, Hiroyuki ; Nakatani, Daisaku ; Ide, Tomomi ; Amano, Tetsuya ; Naito, Hiroaki ; Nagasaka, Hironori ; Kobayashi, Kunihisa. / Triglyceride deposit cardiomyovasculopathy : A rare cardiovascular disorder. In: Orphanet Journal of Rare Diseases. 2019 ; Vol. 14, No. 1.
@article{faf0b4ff8f4c48d5b2604b84e1267f46,
title = "Triglyceride deposit cardiomyovasculopathy: A rare cardiovascular disorder",
abstract = "Triglyceride deposit cardiomyovasculopathy (TGCV) is a phenotype primarily reported in patients carrying genetic mutations in PNPLA2 encoding adipose triglyceride lipase (ATGL) which releases long chain fatty acid (LCFA) as a major energy source by the intracellular TG hydrolysis. These patients suffered from intractable heart failure requiring cardiac transplantation. Moreover, we identified TGCV patients without PNPLA2 mutations based on pathological and clinical studies. We provided the diagnostic criteria, in which TGCV with and without PNPLA2 mutations were designated as primary TGCV (P-TGCV) and idiopathic TGCV (I-TGCV), respectively. We hereby report clinical profiles of TGCV patients. Between 2014 and 2018, 7 P-TGCV and 18 I-TGCV Japanese patients have been registered in the International Registry. Patients with I-TGCV, of which etiologies and causes are not known yet, suffered from adult-onset severe heart disease, including heart failure and coronary artery disease, associated with a marked reduction in ATGL activity and myocardial washout rate of LCFA tracer, as similar to those with P-TGCV. The present first registry-based study showed that TGCV is an intractable, at least at the moment, and heterogeneous cardiovascular disorder.",
author = "Ming Li and Hirano, {Ken Ichi} and Yoshihiko Ikeda and Masahiro Higashi and Chikako Hashimoto and Bo Zhang and Junji Kozawa and Koichiro Sugimura and Hideyuki Miyauchi and Akira Suzuki and Yasuhiro Hara and Atsuko Takagi and Yasuyuki Ikeda and Kazuhiro Kobayashi and Yoshiaki Futsukaichi and Nobuhiro Zaima and Satoshi Yamaguchi and Rojeet Shrestha and Hiroshi Nakamura and Katsuhiro Kawaguchi and Eiryu Sai and Hui, {Shu Ping} and Yusuke Nakano and Akinori Sawamura and Tohru Inaba and Yasuhiko Sakata and Yoko Yasui and Yasuyuki Nagasawa and Shintaro Kinugawa and Kazunori Shimada and Sohsuke Yamada and Hiroyuki Hao and Daisaku Nakatani and Tomomi Ide and Tetsuya Amano and Hiroaki Naito and Hironori Nagasaka and Kunihisa Kobayashi",
year = "2019",
month = "6",
day = "11",
doi = "10.1186/s13023-019-1087-4",
language = "English",
volume = "14",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Triglyceride deposit cardiomyovasculopathy

T2 - A rare cardiovascular disorder

AU - Li, Ming

AU - Hirano, Ken Ichi

AU - Ikeda, Yoshihiko

AU - Higashi, Masahiro

AU - Hashimoto, Chikako

AU - Zhang, Bo

AU - Kozawa, Junji

AU - Sugimura, Koichiro

AU - Miyauchi, Hideyuki

AU - Suzuki, Akira

AU - Hara, Yasuhiro

AU - Takagi, Atsuko

AU - Ikeda, Yasuyuki

AU - Kobayashi, Kazuhiro

AU - Futsukaichi, Yoshiaki

AU - Zaima, Nobuhiro

AU - Yamaguchi, Satoshi

AU - Shrestha, Rojeet

AU - Nakamura, Hiroshi

AU - Kawaguchi, Katsuhiro

AU - Sai, Eiryu

AU - Hui, Shu Ping

AU - Nakano, Yusuke

AU - Sawamura, Akinori

AU - Inaba, Tohru

AU - Sakata, Yasuhiko

AU - Yasui, Yoko

AU - Nagasawa, Yasuyuki

AU - Kinugawa, Shintaro

AU - Shimada, Kazunori

AU - Yamada, Sohsuke

AU - Hao, Hiroyuki

AU - Nakatani, Daisaku

AU - Ide, Tomomi

AU - Amano, Tetsuya

AU - Naito, Hiroaki

AU - Nagasaka, Hironori

AU - Kobayashi, Kunihisa

PY - 2019/6/11

Y1 - 2019/6/11

N2 - Triglyceride deposit cardiomyovasculopathy (TGCV) is a phenotype primarily reported in patients carrying genetic mutations in PNPLA2 encoding adipose triglyceride lipase (ATGL) which releases long chain fatty acid (LCFA) as a major energy source by the intracellular TG hydrolysis. These patients suffered from intractable heart failure requiring cardiac transplantation. Moreover, we identified TGCV patients without PNPLA2 mutations based on pathological and clinical studies. We provided the diagnostic criteria, in which TGCV with and without PNPLA2 mutations were designated as primary TGCV (P-TGCV) and idiopathic TGCV (I-TGCV), respectively. We hereby report clinical profiles of TGCV patients. Between 2014 and 2018, 7 P-TGCV and 18 I-TGCV Japanese patients have been registered in the International Registry. Patients with I-TGCV, of which etiologies and causes are not known yet, suffered from adult-onset severe heart disease, including heart failure and coronary artery disease, associated with a marked reduction in ATGL activity and myocardial washout rate of LCFA tracer, as similar to those with P-TGCV. The present first registry-based study showed that TGCV is an intractable, at least at the moment, and heterogeneous cardiovascular disorder.

AB - Triglyceride deposit cardiomyovasculopathy (TGCV) is a phenotype primarily reported in patients carrying genetic mutations in PNPLA2 encoding adipose triglyceride lipase (ATGL) which releases long chain fatty acid (LCFA) as a major energy source by the intracellular TG hydrolysis. These patients suffered from intractable heart failure requiring cardiac transplantation. Moreover, we identified TGCV patients without PNPLA2 mutations based on pathological and clinical studies. We provided the diagnostic criteria, in which TGCV with and without PNPLA2 mutations were designated as primary TGCV (P-TGCV) and idiopathic TGCV (I-TGCV), respectively. We hereby report clinical profiles of TGCV patients. Between 2014 and 2018, 7 P-TGCV and 18 I-TGCV Japanese patients have been registered in the International Registry. Patients with I-TGCV, of which etiologies and causes are not known yet, suffered from adult-onset severe heart disease, including heart failure and coronary artery disease, associated with a marked reduction in ATGL activity and myocardial washout rate of LCFA tracer, as similar to those with P-TGCV. The present first registry-based study showed that TGCV is an intractable, at least at the moment, and heterogeneous cardiovascular disorder.

UR - http://www.scopus.com/inward/record.url?scp=85067170354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067170354&partnerID=8YFLogxK

U2 - 10.1186/s13023-019-1087-4

DO - 10.1186/s13023-019-1087-4

M3 - Article

C2 - 31186072

AN - SCOPUS:85067170354

VL - 14

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 134

ER -